Vatelizumab

Vatelizumab is an immunomodulator. It binds to integrin alpha 2.[1]

Vatelizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
Targetintegrin alpha 2
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.[2]

References

  1. World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
  2. Mozaffari S, Nikfar S, Abdollahi M (2015). "Inflammatory bowel disease therapies discontinued between 2009 and 2014". Expert Opin Investig Drugs. 24 (7): 949–56. doi:10.1517/13543784.2015.1035432. PMID 25861835. S2CID 26104155.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.